Melanoma is the leading cause of death due to cutaneous malignancy and its incidence is on the rise. Several signaling pathways, including receptor tyrosine kinases, have a role in the development and progression of melanocytic lesions and malignant melanoma. Among those, the hepatocyte growth factor (HGF)/c-met axis is emerging as a critical player because it can play a role in drug resistance. Indeed, 50% of melanoma patients present BRAF mutations, however, all responders develop resistance to the inhibitors typically within one year of treatment. Interestingly, BRAF inhibitors induce reactive oxygen species (ROS) in melanoma cells, therefore, the aim of this study was to investigate a possible interplay between HGF/c-met and ROS sources...
BRAF inhibitors elicit rapid antitumor responses in the majority of patients with BRAF(V600)-mutant ...
The Hepatocyte growth factor (HGF)-mesenchymal-epithelial transition (MET) pathway is deregulated in...
Abstract Metastatic disease in a cancer patient still remains a therapeutic challenge. Metastatic pr...
Therapeutic resistance is a major obstacle to achieving durable clinical responses with targeted the...
peer reviewedBackground: Most melanoma patients with BRAFV600E positive tumors respond well to a com...
Melanoma is a highly aggressive cancer with the poorest prognosis, representing the deadliest form o...
Reactive oxygen species (ROS) play crucial roles in all aspects of melanoma development, however, th...
The discovery of the BRAFV600E mutation led to the development of vemurafenib (PLX4032), a selective...
BRAF inhibitors elicit rapid antitumor responses in the majority of patients with BRAF V600-mutant m...
Hepatocyte growth factor (HGF)/ mesenchymal-epithelial transition factor (c-MET) signaling is involv...
The use of specific inhibitors towards mutant BRAF (BRAFi) and MEK (MEKi) in BRAF-mutated patients h...
BRAF mutations are frequent in cutaneous melanomas and BRAF inhibitors(BRAFi) have shown remarkable ...
ABSTRACT Most melanomas harbor oncogenic BRAF V600 mutations, which constitutively acti-vate the MAP...
BRAF inhibitors elicit rapid antitumor responses in the majority of patients with BRAF(V600)-mutant ...
Circulating glucocorticoids increase during stress. Chronic stress, characterized by a sustained inc...
BRAF inhibitors elicit rapid antitumor responses in the majority of patients with BRAF(V600)-mutant ...
The Hepatocyte growth factor (HGF)-mesenchymal-epithelial transition (MET) pathway is deregulated in...
Abstract Metastatic disease in a cancer patient still remains a therapeutic challenge. Metastatic pr...
Therapeutic resistance is a major obstacle to achieving durable clinical responses with targeted the...
peer reviewedBackground: Most melanoma patients with BRAFV600E positive tumors respond well to a com...
Melanoma is a highly aggressive cancer with the poorest prognosis, representing the deadliest form o...
Reactive oxygen species (ROS) play crucial roles in all aspects of melanoma development, however, th...
The discovery of the BRAFV600E mutation led to the development of vemurafenib (PLX4032), a selective...
BRAF inhibitors elicit rapid antitumor responses in the majority of patients with BRAF V600-mutant m...
Hepatocyte growth factor (HGF)/ mesenchymal-epithelial transition factor (c-MET) signaling is involv...
The use of specific inhibitors towards mutant BRAF (BRAFi) and MEK (MEKi) in BRAF-mutated patients h...
BRAF mutations are frequent in cutaneous melanomas and BRAF inhibitors(BRAFi) have shown remarkable ...
ABSTRACT Most melanomas harbor oncogenic BRAF V600 mutations, which constitutively acti-vate the MAP...
BRAF inhibitors elicit rapid antitumor responses in the majority of patients with BRAF(V600)-mutant ...
Circulating glucocorticoids increase during stress. Chronic stress, characterized by a sustained inc...
BRAF inhibitors elicit rapid antitumor responses in the majority of patients with BRAF(V600)-mutant ...
The Hepatocyte growth factor (HGF)-mesenchymal-epithelial transition (MET) pathway is deregulated in...
Abstract Metastatic disease in a cancer patient still remains a therapeutic challenge. Metastatic pr...